T1	Participants 329 388	65 children with ASD who received one round of DMSA (3 days
T2	Participants 391 491	Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2.
T3	Participants 242 302	children with autism spectrum disorders (ASD) ages 3-8 years
T4	Participants 504 627	49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo
